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Elevated b-catenin levels in human colorectal cancer (CRC) cells lead to increased trans-activation of ‘protumorigenic’ b-catenin/T-
cell factor (TCF) target genes such as cyclin D1. Therefore, possible targets for the anti-CRC activity of nonsteroidal anti-inflammatory
drugs (NSAIDs) are b-catenin and catenin-related transcription (CRT). We tested the antiproliferative activity and the
effects on levels of b-catenin and cyclin D1 protein, as well as CRT (measured using a synthetic b-catenin/TCF-reporter gene
[TOPflash]), of a panel of NSAIDs (indomethacin, diclofenac, sulindac sulphide and sulphone, rofecoxib; range 10–600mM)o n
SW480 human CRC cells in vitro. Following NSAID treatment, there was no consistent relationship between reduced cell
proliferation, induction of apoptosis and changes in b-catenin protein levels or CRT. All the NSAIDs, except rofecoxib, decreased
nuclear b-catenin content and cyclin D1 protein levels in parallel with their antiproliferative activity. However, cyclin D1
downregulation occurred prior to a decrease in total b-catenin protein levels and there was no correlation with changes in CRT,
suggesting the existence of CRT-independent effects of NSAIDs on cyclin D1 expression. In summary, NSAIDs have differential
effects on b-catenin protein and CRT, which are unlikely to fully explain their effects on cyclin D1 and their antiproliferative activity on
human CRC cells in vitro.
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Dysregulation of catenin-related transcription (CRT) is a common
early event in intestinal epithelial cells during human colorectal
carcinogenesis (Wong and Pignatelli, 2002). Loss of both alleles of
the tumour suppressor gene Adenomatous Polyposis Coli (APC)i s
believed to occur prior to development of the benign precursor
lesion of colorectal cancer (CRC), the colorectal adenoma (or
polyp), in the majority of cases of sporadic colorectal carcinogen-
esis (Wong and Pignatelli, 2002). Loss of APC function (or less
commonly ‘gain-of-function’ mutation of the b-catenin gene
CTNNB1) leads to decreased b-catenin degradation and a
subsequent increase in cytoplasmic and nuclear b-catenin protein
levels (Herter et al, 1999; Wong and Pignatelli, 2002). This, in turn,
leads to increased CRT via formation of a transcriptional complex
with T-cell factor (TCF)/lymphoid enhancer factor transcription
factors and subsequent trans-activation of several b-catenin/TCF
target genes such as cyclin D1, peroxisome proliferator-activated
receptor d, matrix metalloproteinase-7 and c-MYC, which are all
understood to play a role in colorectal carcinogenesis (Wong and
Pignatelli, 2002). Therefore, dysregulated CRT is a potential target
for chemoprevention and treatment of CRC.
We, and others, have previously demonstrated that the non-
steroidal anti-inflammatory drug (NSAID) indomethacin decreases
b-catenin protein levels in human CRC cells in vitro and in
neoplastic epithelial cells of dimethyl-hydrazine-induced murine
colonic tumours in vivo (Smith et al, 2000; Brown et al,2 0 0 1 a ;
Hawcroft et al, 2002). In addition, Dihlmann et al (2001) have
reported that indomethacin decreases CRT (measured using the b-
catenin/TCF-reporter gene TOPflash) in human CRC cells. However,
it remains unclear whether modulation of b-catenin expression and/
or CRT is a property shared by other NSAIDs. In our initial study,
downregulation of b-catenin protein was not evident in human CRC
cells treated with aspirin or the experimental selective cycloox-
ygenase (COX)-2 inhibitor NS-398 (Smith et al, 2000). By contrast, it
has been reported that treatment with sulphide and sulphone
metabolites of the NSAID sulindac is associated with decreased b-
catenin protein levels in human CRC cells (Thompson et al,2 0 0 0 ;L i
et al, 2002; Rice et al,2 0 0 3 ) .D i h l m a n net al (2001) have also shown
that aspirin decreases CRT, as well as indomethacin.
No previous study has systematically investigated a series of
NSAIDs in order to determine the relevance of changes in b-
catenin levels and/or CRT to the well-characterised antiprolifera-
tive activity of these drugs on human CRC cells in vitro. Therefore,
we tested the effects of a diverse panel of NSAIDs, with differing
selectivity for the two COX isoforms (Table 1), on the expression of
b-catenin protein, cyclin D1 protein and CRT by SW480 human
CRC cells and correlated these changes with the antiproliferative
activity of each NSAID.
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sMATERIALS AND METHODS
Cell culture
SW480 human sporadic CRC cells (European Collection of Animal
Cell Cultures, Porton Down, UK) were grown in RPMI 1640
medium plus GlutaMAX-It supplemented with 10% (v/v) foetal
bovine serum (FBS), 1000Uml
 1 penicillin and 500Uml
 1
streptomycin (all Invitrogen, Paisley, UK). SW480 human CRC
cells were cultured on tissue culture plastic at 371C, in the presence
of 5% CO2. Cells were routinely subcultured using 0.25% (wv
 1)
trypsin/1mM ethylenediaminetetraacetic acid (EDTA) solution
(Invitrogen). Cells were counted using a haemocytometer and
viability was assessed by exclusion of 0.4% (wv
 1) Trypan blue
(Sigma, Poole, UK). 1 10
5 viable cells were seeded per 35mm well
and were incubated for 96h before NSAID treatment was
commenced.
Drugs and antibodies
Indomethacin and diclofenac were obtained from Sigma. Sulindac
sulphide and sulindac sulphone were obtained from ICN
Biomedicals, Basingstoke, UK. For some experiments, sulindac
sulphide was also obtained from Sigma. Rofecoxib powder was a
kind gift from Merck Sharp & Dohme Ltd., Hoddesdon, Herts.,
UK. A 100mM stock solution of diclofenac was prepared in sterile
distilled water. The other drugs were prepared as 100mM stock
solutions in dimethyl sulphoxide (DMSO; Sigma). Control cultures
contained either DMSO or distilled water at an equivalent (vv
 1)
dilution to that used for the highest concentration of each NSAID.
Mouse monoclonal anti-chicken b-catenin antibody (6F9) and
mouse monoclonal anti-human b-actin antibody (AC15) were
obtained from Sigma. Mouse monoclonal anti-human cyclin D1
(A12) was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Horseradish peroxidase-conjugated rabbit anti-mouse
IgG was obtained from DakoCytomation (Ely, UK).
Cell counting assays
For each experiment, nonadherent and adherent cells in three
individual wells were counted after a 96h culture period (denoted
time 0h). Old medium was removed from the other wells and fresh
medium containing a known concentration of NSAID or solvent
carrier alone, was added to triplicate wells and incubated for 24, 48
or 72h. At each time point, medium containing nonadherent cells
was aspirated from triplicate wells and centrifuged for 5min at
200g, prior to resuspension in a small volume of medium for
counting. Adherent cells were then harvested by trypsinisation and
counted as above. Data are represented as the mean and standard
error of the mean (s.e.m.) cell count (n¼3), for each time point
and drug concentration.
Indirect immunofluorescence
SW480 human CRC cells were grown on glass coverslips in 35mm
wells as described above. After NSAID treatment for 48h, indirect
immunofluorescence for b-catenin was performed on adherent
cells on coverslips as described (Smith et al, 2000).
Fluorescence microscopy of nonadherent SW480 human
CRC cells
Nonadherent SW480 human CRC cells present in medium after
48h NSAID treatment were aspirated, pelleted and resuspended in
4% (wv
 1) paraformaldehyde in phosphate-buffered saline (PBS).
Fixed cells were resuspended in PBS containing 0.5mgml
 1
Hoechst 33258 (ICN Biomedicals). The percentage number of
morphologically apoptotic cells was counted by fluorescence
microscopy as described (Ko et al, 2002).
Measurement of caspase-3/-7 activity
SW480 human CRC cells (3.4 10
3). were placed in individual
wells of a flat-bottomed 96-well plate and cultured for 96h in order
to mirror the experimental protocol used for cell counting assays.
Cells were treated with NSAIDs or an equivalent dilution of carrier
solvent for 48h before addition of caspase substrate. Caspase-3/-7
activity was measured at 90min by a fluorescence plate reader
(FLUOstar Galaxy, Isogen Life Science, Maarssen, The Nether-
lands) as per the manufacturer’s instructions (Apo-ONEt homo-
geneous caspase-3/-7 assay, Promega UK Ltd., Southampton, UK).
Data are presented as the mean (þs.e.m.) percentage fluorescence
value for each NSAID compared with the appropriate carrier
control (n¼3). None of the NSAIDs had any direct activity on the
caspase substrate in ‘no cells’ control wells (data not shown).
Western blot analysis
Adherent cells were lysed in 50mM Tris-HCl (Melford Labs. Ltd.,
Ipswich, UK) buffer (pH 7.2) containing 0.137 M sodium chloride
(BDH, Poole, UK), 1% Brij 96 (Fluka, Gillingham, UK), 1mM EDTA
and Completet protease inhibitor cocktail (Roche Diagnostics,
Germany). Whole cell lysates were prepared as described
(Hawcroft et al, 2002) and the total protein concentration was
determined using a BioRad DC kit (BioRad, Hemel Hempstead,
UK). Sodium dodecyl–sulphate polyacrylamide gel electrophoresis
(SDS–PAGE) was performed on 20mg total protein aliquots,
alongside MagicMark Western Standards (Invitrogen, Paisley,
UK), using 10% NuPAGE Bis-Tris 1.0mm gels (Invitrogen, Paisley,
UK) as described (Hawcroft et al, 2003). Proteins were transferred
to Hybond P polyvinylidene fluoride membranes (Amersham
Pharmacia Biotech, Amersham, UK) by wet blotting. Membranes
were blocked with 5% (wv
 1) dried skimmed milk powder in PBS
(blocking solution) containing 0.05% (vv
 1) Tween 20 (Sigma) for
1h at 201C. Membranes were probed with primary antibodies
against b-catenin (1/5000 dilution) or b-actin (1/2500 dilution) in
blocking solution for 1h at 201C. Anti-cyclin D1 antibody (1/500 in
blocking solution) was applied overnight at 41C. Horseradish
peroxidase-conjugated secondary antibody (1/5000 or 1/1000 [for
cyclin D1] dilution) in blocking solution was incubated with the
Table 1 The COX isoform selectivity of the NSAIDs used
Drug
a
COX-1 IC50
(lM)
b
COX-2 IC50
(lM)
b COX selectivity
Indomethacin 0.013 0.13 COX-14COX-2
Diclofenac 0.075 0.02 COX-24COX-1
Sulindac sulphide 1.9 1.21 COX-1¼COX-2
Sulindac sulphone
c N/A N/A N/A
Rofecoxib 63 0.31 COX-244COX-1
aIndomethacin was included as a positive control as it has antineoplastic activity and
decreases b-catenin protein levels in intestinal epithelial cells in vitro and in vivo (Smith
et al, 2000; Brown et al, 2001a). The chemically related prodrug sulindac is converted
in vivo to a sulphide or, to a lesser extent, a sulphone metabolite, which have both
been demonstrated to possess anti-CRC activity in vitro and in vivo (Piazza et al,
1997a, b; McEntee et al, 1999; Brown et al, 2001b). Diclofenac was included as it is a
widely used, well tolerated drug, for which there is only scanty evidence for anti-CRC
activity (Hixson et al, 1994). Rofecoxib possesses high selectivity for COX-2 and so
may find increased acceptability as a possible chemoprevention agent due to
improved upper gastrointestinal tolerability (Bombardier et al, 2000).
bThe precise
IC50 value for COX-1 and COX-2 inhibition by individual NSAIDs is dependent on
the assay used but the overall COX isoform selectivity of each NSAID is usually
consistent between methodologies. The IC50 values quoted are from the large study
by Warner et al (1999).
cSulindac sulphone has no COX inhibitory activity.
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smembrane for 1h at 201C. Immunoreactive protein was detected
using ECL chemiluminescence (Pierce, Chester, UK).
Densitometric analysis
A Bio-Rad Molecular Imager FX was used to quantify individual
bands. The background intensity was subtracted and the bands
were quantified using Quantity One software (Bio-Rad). The
relative intensity of the b-catenin band to the b-actin band was
determined. Each b-catenin/b-actin ratio was then expressed as a
percentage of the control b-catenin/b-actin ratio (which was given
an arbitrary value of 100%). Data are represented as the mean (and
s.e.m.) percentage of the control b-catenin/b-actin ratio value
(n¼3), for each time point and drug treatment.
Transient DNA transfection and dual-luciferase reporter
assays
Experiments on the effect of NSAIDs on CRT, using the b-catenin/
TCF-reporter construct TOPflash (Korinek et al, 1997), were
performed in an identical manner to that described for the cell
proliferation and apoptosis assays, except that transient DNA
transfection of cells occurred during a 3h period prior to addition
of drug or carrier control. GeneJuicet transfection reagent
(Novagen, Madison, WI, USA) was added to serum-free RPMI
1640 medium plus GlutaMAX-It and incubated for 5min before
addition of the appropriate plasmid DNA (TOPflash or FOPflash
(1mg; both Upstate Biotechnology, Lake Placid, NY, USA) with
pRL-TK (0.5mg; Promega). The GeneJuicet-DNA mix was
incubated for 30min at 201C before incubation with cells for 3h
at 371C. The transfection medium was removed and fresh culture
medium, containing drug or carrier control, was added. After
incubation for 48h at 371C, cells were washed once with PBS, lysed
with Passive Lysis Buffer and Dual-Luciferase reporter assays
(both Promega) were performed as per the manufacturer’s
instructions. Firefly (TOPflash or FOPflash) luciferase activity
was corrected for Renilla luciferase activity (pRL-TK) to control
for transfection efficiency. In order to exclude any CRT-
independent effect on thymidine kinase (tk) minimal promoter
activity of TOPflash, TOPflash activity was normalised to the ratio
of the FOPflash (which contains an identical tk promoter) activity
between NSAID-treated and control cells, termed the FOPflash
ratio. Data are expressed as the mean (and s.e.m.) of triplicate
values of the normalised TOPflash activity, with the corresponding
drug-treated/control cell FOPflash activity ratio.
Statistical analysis
One-way analysis of variance (ANOVA) was used to determine the
significance of the effect of different concentrations of NSAIDs on
cell number, the b-catenin/b-actin protein ratio and normalised
TOPflash activity. The Bonferroni test was used for post hoc
comparison of the effects of particular NSAID concentrations
compared with control cell cultures. Statistical significance was
assumed if the P-value was less than or equal to 0.05.
RESULTS
Effect of NSAIDs on SW480 human CRC cell proliferation
and apoptosis
Our previous study demonstrated that indomethacin treatment
induced G1 arrest and apoptosis (measured by flow cytometric
DNA content analysis), as well as decreased b-catenin protein
levels, in four human CRC cell lines, regardless of the presence of
mutant APC alleles or COX-2 expression (Smith et al, 2000).
Therefore, we used only one human CRC cell line for the current
study. We chose SW480 human CRC cells as they contain no
functional APC and hence have high basal CRT and cyclin D1
expression (Shtutman et al, 1999; Hawcroft et al, 2002). In
addition, SW480 human CRC cells do not express COX-2 (Smith
et al, 2000) and therefore reflect the COX expression pattern of
intestinal epithelial cells at early stages of colorectal carcinogen-
esis, of most relevance to CRC chemoprevention (Chapple et al,
2000).
The viability of adherent SW480 human CRC cells was
consistently greater than 95%. Therefore, the number of adherent
cells at each time point was used to measure net cell proliferation.
We, and others, have previously demonstrated that, following
NSAID treatment of human CRC cells, the number of nonadherent
cells accurately reflects the degree of apoptosis that has occurred
(Shiff et al, 1996; Piazza et al, 1997b; Qiao et al, 1997; Smith et al,
2000). In the experiments described herein, the nonadherent cell
population consisted of greater than 90% morphologically
apoptotic cells following treatment with all the NSAIDs except
rofecoxib (Figure 1F–J). Therefore, the number of nonadherent
SW480 human CRC cells, at each time point, was used as a
measure of apoptosis of NSAID-treated SW480 human CRC cells.
There was a 2–3-fold increase in the number of adherent SW480
human CRC cells over 72h in the presence of solvent carrier alone,
in all experiments (Figure 1A–E). In the absence of drug
treatment, there was only a small number of morphologically
nonapoptotic, nonadherent cells (approximately 1 10
5 cells/
24h), which did not increase during the 72h experiment (Figure
1F–J).
We chose to include indomethacin in the panel of NSAIDs tested
in this study in order to act as a control which would aid
comparison with our previous studies on indomethacin and b-
catenin (Smith et al, 2000; Hawcroft et al, 2002). Treatment with
indomethacin resulted in a concentration-dependent reduction in
proliferation (Figure 1A). The decrease in adherent SW480 human
CRC cells was statistically significant at all three time points when
indomethacin was present at a concentration equal to or above
400mM (Figure 1A). Indomethacin treatment was associated with a
small increase in the degree of apoptosis of SW480 human CRC
cells measured by nonadherent cell counting in this experiment
(Figure 1F). However, proapoptotic activity of indomethacin was
readily apparent in the caspase-3/-7 activity assay (Figure 2).
Diclofenac treatment was also associated with a concentration-
dependent antiproliferative effect on SW480 human CRC cells,
which reached statistical significance at concentrations equal to
and above 200mM (Figure 1B). Unlike indomethacin, the anti-
proliferative activity of diclofenac associated with concentrations
above 200mM, occurred in conjunction with a significant decrease
in apoptosis between 24 and 72h (Figure 1G). Data from the
caspase activity assay were consistent with these findings, in that
the highest concentration of diclofenac (600mM) did not induce
caspase activation in SW480 human CRC cells at 48h compared
with control cells (Figure 2).
The two metabolites of sulindac, sulphide and sulphone, both
demonstrated concentration-dependent antiproliferative activity
against SW480 human CRC cells (Figure 1C–D). However, the
approximate IC50 value for the antiproliferative effect of sulindac
sulphide at 72h (100mM) was approximately half that of sulindac
sulphone (200mM). Treatment with sulindac sulphide at concen-
trations at and above 200mM was associated with a pronounced
increase in apoptosis (Figure 1H), unlike equivalent or higher
concentrations of sulindac sulphone (Figure 1I). Interestingly,
treatment with 300mM sulindac sulphide was associated with a
reduction (not an increase, unlike the other proapoptotic NSAIDs,
including sulindac sulphone) in caspase-3/-7 activity (Figure 2).
Rofecoxib (up to 200mM) had little effect on the proliferation of
SW480 human CRC cells compared with the other NSAIDs that
were tested in this study (Figure 1E). There was a small decrease in
the adherent cell number at 72h following incubation with 100 and
200mM rofecoxib (Figure 1E) but this did not reach statistical
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Figure 1 Effect of NSAIDs on SW480 human CRC cell proliferation and apoptosis. The number of adherent (viable) cells and nonadherent (apoptotic)
cells were counted at 24–72h time points. Data are expressed as the mean and s.e.m. number of adherent cells ( 10
6; parts A–E) and nonadherent cells
( 10
5; parts F–J). For ease of analysis, error bars are sometimes unidirectional. * Po0.05, ** Po0.01, *** Po0.001 for all time points for a given
concentration of a NSAID compared with the carrier control (one-way ANOVA with post hoc Bonferroni test). Parts F–J include the mean (7s.e.m.)
percentage number of Hoechst 33258-stained, morphologically apoptotic nonadherent cells after 48h treatment with the highest concentration of NSAID
(n¼3).
NSAIDs and b-catenin in colorectal cancer cells
SH Gardner et al
156
British Journal of Cancer (2004) 91(1), 153–163 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
ssignificance. No increase in nonadherent SW480 human CRC cells
was evident following rofecoxib treatment and only 3.7% of such
cells had morphological characteristics of apoptosis (Figure 1J). In
addition, rofecoxib did not induce caspase-3/-7 activity in SW480
human CRC cells (Figure 2). We were unable to test rofecoxib at
concentrations higher than 200mM because of poor solubility of the
stock solution in aqueous cell culture medium.
Effect of NSAIDs on b-catenin protein levels in SW480
human CRC cells
Indomethacin treatment, at concentrations equal to and above
200mM, was associated with a time-dependent decrease in b-
catenin protein levels, which reached statistical significance at 72h
for the 600mM concentration (Figure 3A). Similar changes in b-
catenin protein levels were evident following diclofenac treatment,
although these changes did not attain statistical significance
(Figure 3B). Diclofenac treatment was associated with a reduction
in nuclear and cytoplasmic b-catenin immunofluorescence signal,
with a corresponding increase in membranous b-catenin localisa-
tion, as we have previously described for indomethacin (Figure 4B;
Smith et al, 2000). Treatment with sulindac sulphide was
associated with a time- and concentration-dependent reduction
in b-catenin protein levels (Figure 3C). There was a 60% reduction
in b-catenin protein level after 72h incubation with 200mM
sulindac sulphide which was statistically significant (Figure 3C).
Treatment with 120mM sulindac sulphide for 48h was associated
with a reduction in nuclear b-catenin content and increased
membranous b-catenin localisation in a similar manner to
indomethacin and diclofenac (data not shown). However, a higher
concentration of sulindac sulphide (300mM) induced an apparent
increase in nuclear b-catenin protein content (Figure 4C), which
may be explained by nuclear shrinkage producing the false
impression of increased b-catenin content or selection of ‘resistant’
cells with high nuclear b-catenin content. No significant changes in
total b-catenin protein levels were observed in SW480 CRC cells
treated with higher concentrations of sulindac sulphone
(Figure 3D). However, treatment with sulindac sulphone
(600mM) was associated with reduced nuclear b-catenin protein
(data not shown) consistent with a previous report (Rice et al,
2003). Rofecoxib treatment had no significant effect on b-catenin
protein levels or localisation in SW480 human CRC cells (Figures
3E and 4D).
Effect of NSAIDs on cyclin D1 protein levels in SW480
human CRC cells
Previously, we have demonstrated that indomethacin treatment of
SW480 human CRC cells is associated with decreased expression of
the b-catenin/TCF target gene cyclin D1 (Smith et al, 2000;
Hawcroft et al, 2002). Therefore, we were interested to determine
whether the effects of the NSAIDs on proliferation and apoptosis
described above were associated with changes in the cellular
content of cyclin D1 protein, which is recognised to play a crucial
role in progression through the G1 phase of the cell cycle (Lukas
et al, 1996). Treatment with all the NSAIDs, except rofecoxib, was
associated with a marked decrease in cyclin D1 protein levels, such
that there was a complete absence of cyclin D1 protein in SW480
human CRC cells after treatment with high (4200mM) concentra-
tions of NSAIDs (Figure 3A–E). Therefore, densitometric analysis
of cyclin D1 protein levels was not carried out. A decrease in cyclin
D1 protein was apparent by 24h and this effect increased in a
concentration-dependent manner. The time and magnitude of the
decrease in cyclin D1 protein correlated well with the antiproli-
ferative activity of individual NSAIDs (compare Figures 1 and 3;
Table 2). However, a simple relationship between alterations in
cyclin D1 protein levels and the corresponding change in total b-
catenin protein levels, associated with individual NSAIDs, was not
apparent (Figure 3). For example, a marked decrease in cyclin D1
protein in indomethacin-, diclofenac- and sulindac sulphide-
treated cells was associated with quantitatively smaller changes in
b-catenin protein content, which tended to occur at later time
points (Figure 3A–C). Moreover, the abolition of cyclin D1 protein
expression in cells treated with high (4400mM) concentrations of
sulindac sulphone did not occur in association with significant
changes in b-catenin protein content (Figure 3D). In this context,
it is perhaps more relevant to compare changes in cyclin D1
protein levels and nuclear b-catenin content. There was a good
correlation between the reduction in nuclear b-catenin content
observed by immunofluorescence and the decrease in cyclin D1
protein that was apparent after treatment with any given NSAID
(Figures 3 and 4; Table 2)
Effect of NSAIDs on CRT in SW480 human CRC cells
We were then interested to determine the effects of the panel of
NSAIDs on CRT in SW480 human CRC cells. Cells were transiently
transfected with a synthetic TCF reporter plasmid TOPflash (which
consists of three TCF binding sites upstream of a minimal tk
promoter and the Luciferase open reading frame), prior to
treatment with NSAIDs. TOPflash activity in control SW480
human CRC cells was consistently greater than 40-fold higher
than the corresponding FOPflash activity, confirming significant
basal CRT in cells lacking functional APC alleles. In order to
exclude nonspecific effects of NSAIDs on gene expression,
TOPflash activity in NSAID-treated SW480 human CRC cells was
corrected for any drug-induced effects on FOPflash (which is
identical to TOPflash except that it contains mutant inactive TCF
binding sites). NSAID treatment was associated with numerically
small, variable effects on FOPflash activity, which are denoted as
the ratio of FOPflash activity in treated vs control SW480 human
CRC cells (Figure 5).
Figure 5 (in comparison with Figure 3) demonstrates that there
was no consistent relationship between CRT, measured by
TOPflash activity, and changes in either total b-catenin protein
levels, nuclear b-catenin localisation or cyclin D1 protein levels in
SW480 human CRC cells treated with NSAIDs. CRT was
significantly reduced by treatment with diclofenac or sulindac
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ssulphide for 48h in a concentration-dependent manner, in parallel
with reduced b-catenin protein levels, although changes in b-
catenin protein levels associated with the former drug did not
reach statistical significance (compare Figures 5B and 3B).
Treatment with indomethacin was associated with a biphasic
pattern of changes in CRT, such that CRT was increased in the
presence of 200–400mM indomethacin but the increase was
abolished at a higher concentration (600mM) of indomethacin
(Figure 5A). Treatment with the two NSAIDs that did not appear to
be associated with changes in total b-catenin protein levels
(sulindac sulphone and rofecoxib) was not associated with reduced
CRT (Figure 5D and E). Indeed, certain concentrations of these
two agents were actually associated with increased normalised
TOPflash activity (Figure 5D and E).
Levels of cyclin D1 protein in SW480 human CRC cells after
therapy with different concentrations of diclofenac and sulindac
sulphide for 48h did mirror TOPflash activity but not for
indomethacin or sulindac sulphone, which were variably asso-
Figure 4 Effect of NSAIDs on b-catenin localisation in SW480 human CRC cells. Indirect immunofluorescence for b-catenin was performed on adherent
cells following 48h treatment with each NSAID. Confocal microscopy was performed at the same magnification for all cell preparations ( 1000). (A) Cells
incubated in the presence of 0.6% (vv
 1) DMSO, (B) diclofenac (600mM)-treated cells demonstrating increased membranous b-catenin localisation (arrow)
with decreased nuclear (double arrow) and cytoplasmic b-catenin intensity (similar changes were apparent following treatment with 600mM indomethacin
and 120mM sulindac sulphide), (C) sulindac sulphide (300mM)-treated cells exhibiting shrunken nuclei with prominent ‘speckled’ b-catenin localisation, (D)
rofecoxib (200mM)-treated cells demonstrating a minimal reduction in nuclear b-catenin signal.
Table 2 Summary of the effects of NSAIDs on SW480 human CRC cells
Drug
Anti-
proliferative
activity
a
Pro-apoptotic
activity
a
Effect on total b-
catenin protein
levels
b
Effect on
nuclear b-
catenin content
b
Effect on cyclin
D1
b Effect on CRT
b,c
Indomethacin ++ ++ kk k k - *
Diclofenac ++ + kk k k k
Sulindac sulphide +++ +++ kk k
d kk k
Sulindac sulphone ++ ++ -k k - *
Rofecoxib +   --- - *
a ¼none; +¼weak; ++¼moderate; +++¼strong.
b-¼No change; k¼decrease; kk¼marked decrease.
c-*Indicates that at least one concentration of the NSAID was
associated with an increase in CRT compared with control cells.
dNuclear b-catenin content was reduced after treatment with 120mM sulindac sulphide for 48h. A paradoxical
increase in nuclear localisation of b-catenin was apparent after incubation with 300mM sulindac sulphide for 48h.
NSAIDs and b-catenin in colorectal cancer cells
SH Gardner et al
159
British Journal of Cancer (2004) 91(1), 153–163 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s7
0
20
40
60
80
100
120
140
160
180
200
220
600
400
200
100
C
N
o
r
m
a
l
i
s
e
d
 
T
O
P
F
L
A
S
H
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
6
0
10
20
30
40
50
60
70
80
90
100
600
400
200
100
C
N
o
r
m
a
l
i
s
e
d
 
T
O
P
F
L
A
S
H
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
7
0
10
20
30
40
50
60
70
80
90
100
600
400
200
100
C
N
o
r
m
a
l
i
s
e
d
 
T
O
P
F
L
A
S
H
 
l
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y
Diclofenac
** *
*
FOPflash
ratio
- 2.4 3.5 4.5 3.8
Indomethacin AB
C
E
D
*
*
FOPflash
ratio
- 0.4 0.4 0.2 0.3
7
0
10
20
30
40
50
60
70
80
90
100
200
300
100
50 
C
N
o
r
m
a
l
i
s
e
d
 
T
O
P
F
L
A
S
H
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
Sulindac sulphide
*
*
*
*
*
FOPflash
ratio
FOPflash
ratio
- 1.7 1.8 10.6 2.7 - 1.2 1.8 1.7 1.7
Sulindac sulphone
6
0
10
20
30
40
50
60
70
80
90
100
200
100
50
10
C
N
o
r
m
a
l
i
s
e
d
 
T
O
P
F
L
A
S
H
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
Rofecoxib
*
FOPflash
ratio
- 1.1 0.9 1.1 0.5
Figure 5 Effect of NSAIDs on CRT in human SW480 CRC cells. Dual-luciferase assays were performed on SW480 human CRC cells transfected with
TOPflash or FOPflash vectors, along with Renilla pRL-TK plasmid, and then treated for 48h with differing concentrations (in mM) of NSAIDs. TOPflash and
FOPflash activities were corrected for transfection efficiency using the Renilla pRL-TK activity. The effect of NSAIDs on TOPflash activity was corrected for
CRT-independent effects on the minimal tk promoter downstream of the TCF binding sites by normalisation against the ratio of FOPflash (that contains the
identical promoter) activity in drug-treated vs control cells (FOPflash ratio). Data from triplicate experiments are expressed as the meanþs.e.m. normalised
TOPflash activity for each drug concentration. The corresponding mean FOPflash ratio (n¼3) is noted below each bar. *Po0.05 for the difference in
normalised TOPflash activity compared with control cells (one-way ANOVA with post hoc Bonferroni test).
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decreased cyclin D1 protein levels (compare Figures 3 and 5).
DISCUSSION
This study has revealed that all the NSAIDs tested, except the
selective COX-2 inhibitor rofecoxib, have significant antiprolifera-
tive activity against SW480 human CRC cells, which is associated
with decreased cyclin D1 protein expression (Table 2). Although
there was a good correlation between the antiproliferative activity
of each NSAID and the time-course and extent of downregulation
of the cell cycle regulator cyclin D1, the reduction in total b-catenin
protein levels and changes in CRT demonstrated for individual
NSAIDs bore no such relationship (Table 2). However, the
reduction in nuclear b-catenin content observed by immunofluor-
escence did parallel changes in cyclin D1 protein levels (Table 2).
SW480 human CRC cells do not express COX-2 (Smith et al,
2000). Therefore, this cell line may not be representative of all
colorectal epithelial cells at early stages of colorectal carcinogen-
esis (a minority of which contain COX-2 protein; Chapple et al,
2000). However, several Groups have not reported differences in
the effects of NSAIDs on COX-2-positive compared with COX-2-
negative human CRC cell lines (Hixson et al, 1994; Yamazaki et al,
2002), including changes in b-catenin levels (Rice et al, 2003), thus
justifying the use of SW480 human CRC cells in our experiments.
Although the effects of the NSAIDs used in this study on
proliferation and apoptosis of SW480 human CRC cells have been
previously described (Hixson et al, 1994; Piazza et al, 1997b; Smith
et al, 2000; Yamazaki et al, 2002), there has been no previous study
of the effects of a series of NSAIDs on expression of b-catenin and
the cell cycle regulatory protein cyclin D1 by these cells. Therefore,
we decided to confirm the data on NSAID-induced changes in
SW480 human CRC cell kinetics so that a direct comparison of
changes in b-catenin and cyclin D1 protein levels could be made
with effects on proliferation and apoptosis in the same set of
experiments. The concentration range that was used for each
NSAID was based on previous data from experiments using human
CRC cells (Hixson et al, 1994; Piazza et al, 1997b; Smith et al, 2000;
Yamazaki et al, 2002). The question of whether the high
concentrations of NSAIDs, which are employed in studies using
human CRC cells in vitro, are relevant to the antineoplastic activity
of these agents in vivo is currently a subject of debate (Hwang et al,
2002; Hull et al, 2003). However, the in vivo relevance of our
current findings on the effect of NSAIDs on b-catenin levels and
localisation has been confirmed in rodent models (McEntee et al,
1999 [sulindac]; Brown et al, 2001a [indomethacin, sulindac
sulphone]; Oshima et al, 2001 [rofecoxib]).
As expected, all the NSAIDs had antiproliferative activity in the
100–600mM concentration range. The IC50 values for the
individual NSAIDs were similar to those previously reported
(Hixson et al, 1994; Piazza et al, 1997b; Yamazaki et al, 2002). As
previously described, rofecoxib had little antiproliferative activity
compared with the other NSAIDs that were tested (Yamazaki et al,
2002), although the concentration range of this NSAID was
restricted by poor solubility. We also confirmed a previous report
that the sulphide metabolite of sulindac has more potent
antiproliferative activity than sulindac sulphone (Piazza et al,
1997b). The effect of the individual NSAIDs on induction of
apoptosis was smaller and more variable than the antiproliferative
activity. Sulindac sulphide was the only NSAID that induced
significant apoptosis (measured by nonadherent cell counting) in
parallel with its antiproliferative activity. The small increase in
apoptosis associated with the lower concentrations of diclofenac
and, to a lesser extent, with sulindac sulphone implies that
proapoptotic activity of these NSAIDs may predominate at these
concentrations and that proapoptotic and antiproliferative effects
of certain NSAIDs may be independent. The decrease in apoptotic
cell number associated with higher concentrations of diclofenac
may represent a reduction in apoptosis, which would normally
occur at cell confluency, rather than a direct NSAID-induced effect
on the apoptosis rate. There are relatively few data on the
proapoptotic activity of NSAIDs on human CRC cells. However, it
has been noted that the two sulindac metabolites do have
differential effects on apoptosis of SW480 human CRC cells
(Piazza et al, 1997b). Recently, it has been reported that human
colorectal mucosal apoptosis rates are not increased in NSAID
users (Martin et al, 2002). This suggests that any proapoptotic
effect of NSAIDs may also play only a minor role in their
chemopreventative activity in vivo.
Although caspase-3 cleavage has been linked to sulindac-
induced apoptosis of human CRC cells in vitro (Rice et al, 2003),
assay of caspase-3 activity has not been performed previously in
studies of the effect of NSAIDs on human CRC cells in vitro. There
was a good correlation between induction of caspase activity and
proapoptotic activity of individual NSAIDs, except for sulindac
sulphide. Sulindac sulphide treatment is associated with cleavage
of caspase-3 in HCT116 human CRC cells (Rice et al, 2003), which
should increase caspase activity. However, sulindac sulphide
treatment (300mM) was associated with decreased caspase-3/-7
activity in SW480 human CRC cells. Further investigation of
whether sulindac sulphide has direct caspase inhibitory activity is
now required.
Treatment with all NSAIDs, with the exception of rofecoxib, was
associated with a reduction in total b-catenin protein levels of
varying degrees (Table 2). Upregulation of b-catenin expression
during colorectal carcinogenesis leads to accumulation of nuclear
b-catenin, which is a prerequisite for increased CRT (Takahashi
et al, 1998; Herter et al, 1999). Importantly, we observed that
treatment with NSAIDs, except rofecoxib, was associated with a
reduction in nuclear b-catenin content in SW480 human CRC cells.
This is consistent with existing in vitro and in vivo data
(Thompson et al, 2000; Rice et al, 2003; Boon et al, 2004), which
includes the report of Brown et al (2001a), in which treatment with
a similar panel of NSAIDs (indomethacin, sulindac, sulindac
sulphone and meloxicam), but not celecoxib, was associated with
decreased nuclear b-catenin staining in DMH-induced CRCs in
rats. Although immunofluorescence for b-catenin protein does not
easily allow quantitation of b-catenin levels, this technique may
have more relevance to studies of the effects of NSAIDs on WNT
signalling in human CRC cells than measurement of total cellular
b-catenin levels.
The close relationship between the antiproliferative activity of
individual NSAIDs and reduction in cyclin D1 protein levels in
SW480 human CRC cells that we observed is in keeping with the
known function of cyclin D1 as a cell cycle regulator of G1–S
phase transition (Lukas et al, 1996). However, it has yet to be
determined whether downregulation of cyclin D1 is a primary
effect of NSAIDs or is secondary to G1 arrest induced by these
drugs by another mechanism(s). Consistent with a central role for
cyclin D1 in cell cycle control, cyclin D1 is a downstream target for
several signalling pathways and has a complex promoter with
multiple transcription factor binding elements (Lukas et al, 1996;
Wang et al, 2001). Cyclin D1 is a known b-catenin/TCF target gene
(Shtutman et al, 1999). Therefore, one possible mechanism by
which NSAIDs may downregulate cyclin D1 expression is by
decreased CRT. Dihlmann and colleagues have reported that
indomethacin and aspirin reduced CRT (measured using synthetic
TCF-reporter genes, which included either a minimal c-FOS or
SV40 promoter), as well as cyclin D1 mRNA and protein levels, in
SW948 human CRC cells (Dihlmann et al, 2001). We have also
previously demonstrated that indomethacin treatment is asso-
ciated with reduction in cyclin D1 mRNA and protein levels in
SW480 human CRC cells (Hawcroft et al, 2002). However,
mutation of the single functional TCF-binding element in the
cyclin D1 promoter did not significantly abrogate the decrease in
NSAIDs and b-catenin in colorectal cancer cells
SH Gardner et al
161
British Journal of Cancer (2004) 91(1), 153–163 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
scyclin D1 promoter activity induced by indomethacin, suggesting
that other, CRT-independent mechanisms of action of indometha-
cin on the cyclin D1 promoter are likely to exist (Hawcroft et al,
2002). Our observational data showing that there is no simple
relationship between NSAID-induced changes in cyclin D1 protein
levels and CRT (measured by TOPflash activity), despite reduction
in nuclear b-catenin content, is consistent with the concept that
reduced cyclin D1 expression and inhibition of cell proliferation of
human CRC cells occurs via a mechanism that is not simply
explained by decreased CRT, subsequent to reduced b-catenin
levels. This is perhaps not surprising given the complexity of
control of cyclin D1 expression and the fact that NSAIDs are likely
to have several different mechanisms of antineoplastic activity
(Lukas et al, 1996; Hwang et al, 2002; Hull et al, 2003). Li et al have
recently reported that sulindac sulphone induced a parallel
decrease in b-catenin and cyclin D1 protein expression in SW480
human CRC cells (Li et al, 2002), building on an earlier report
from the same group (Thompson et al, 2000). These authors
overexpressed N-terminal mutant b-catenin protein in SW480
human CRC cells, which partially abrogated the exisulind-induced
decrease in cyclin D1 protein and partially protected the cells from
exisulind-induced apoptosis (Li et al, 2002). These data are also
consistent with the concept that NSAIDs are likely to reduce cyclin
D1 expression by CRT-dependent and -independent mechanisms.
The conflicting data on the association between NSAID-induced
changes in cyclin D1 expression and CRT suggest that cyclin D1
should only be used as a ‘read-out’ of CRT activity in human CRC
cells with caution.
Our data on the effect of indomethacin on TOPflash activity
conflict with those of Dihlmann et al (2001). However, our data on
the effect of sulindac on TOPflash activity are similar to those
recently reported by Boon et al (2004). Another study, which
included experiments on the effect of sulindac on TOPflash activity
in human CRC cells, reported that treatment of SW620 human
CRC cells with a very high concentration (1600mM) of sulindac for
24h was associated with increased ‘Tcf activity’ based on an
increase in the TOPflash/FOPflash ratio (Bordonaro et al, 1999).
Sulindac (10mM for 48h) has been demonstrated to have no
inhibitory effect on TOPflash activity in HEK293 cells (Orner et al,
2002) suggesting cell-type-specific activity of sulindac on CRT.
Possible explanations for the discrepant data from experiments
using human CRC cells include variable CRT-independent effects
of NSAIDs on TOPflash constructs with different downstream
promoters and/or variations in the methods used to analyse
TOPflash and FOPflash activity data, which may not address
adequately the issue of nonspecific effects of NSAID treatment on
reporter gene expression.
In summary, NSAIDs have differential effects on b-catenin
protein, cyclin D1 protein and CRT in human CRC cells. There is
no simple relationship between alterations in total b-catenin
protein levels and nuclear b-catenin localisation induced by
NSAIDs and changes in CRT. Evidence is emerging that NSAIDs
may also modulate WNT signalling via changes in the phosphor-
ylation status of b-catenin and glycogen synthase kinase-3
(Dihlmann et al, 2003; Boon et al, 2004). More refined methods
of testing the effects of NSAIDs on CRT in intestinal epithelial cells
in vivo are now required in order to investigate further the activity
of NSAIDs against this pivotal signal transduction mechanism in
colorectal carcinogenesis.
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